InnoStar is proud to have played a central, critical role in advancing UniXell’s landmark UX-GIP001 injection to FDA IND approval – the world’s first iPSC-derived allogeneic cell therapy for epilepsy to enter clinical development.

As the trusted nonclinical safety evaluation partner, InnoStar designed and delivered a full suite of rigorous, FDA-aligned safety studies via intracranial administration, supporting UniXell’s successful IND submission. Our GLP-compliant platform, operating to NMPA, ICH, FDA, and OECD standards, combined scientific rigor, technical precision, and global regulatory expertise to de-risk development and accelerate this life-changing therapy to the clinic.

Epilepsy impacts over 70 million people worldwide. One-third develop drug-resistant disease with limited options. UX-GIP001 targets the core pathological mechanism by restoring GABAergic interneuron function, moving beyond symptom management to disease-modifying repair.

At InnoStar, we enable revolutionary cell and gene therapies to reach patients faster. We are honored to partner with innovators like UniXell to redefine treatment possibilities for neurological disorders.

Congratulations to the entire UniXell team!